Wednesday, 21 Feb 2018

You are here

EULAR/EFORT Taskforce on the Management of Fragility Fractures

The morbidity associated with osteoporosis-related fragility fractures imposes tremendous socioeconomic and medical impact on patients and society.

To address this the European League Against Rheumatism (EULAR) and the European Federation of National Associations of Orthopedics and Traumatology (EFORT) united their efforts in a combined task force to create evidence-based recommendation on optimal management of patients with fragility fracture and prevention of subsequent fractures.

After systematic literature review data were categorized according to quality and the consensus the of task force resulted in 10 recommendations which is briefly summarized below:

  1.  Preop- and perioperative management: Multidisciplinary approach and adequate pain relief, appropriate fluid management and surgery within 48 hours of injury.  Delay to the operation to enable optimization of acute medical problems has to be weighed up against the effects of prolonging pain and immobility.
  2. Orthogeriatric care:  Preventable perioperative complication with high risk of mortality and morbidity such as delirium, DVT, pressure sores and malnutrition should be prevented. Comprehensive geriatric assessment and multidisciplinary comanagement recommended.
  3. Treatment of fracture: Balanced approach to operative versus non-operative treatment is required  and should depend on the type of fracture and the individual patient
  4. Organization of post fracture care:  Individual approach in preventing secondary fractures advised. The Fracture Liaison Service (FLS) is the most effective organizational structure for risk evaluation and treatment initiation per systematic review and meta-analysis. A nominated coordinator significantly improves the implementation of osteoporosis treatment after a fragility fracture
  5. Evaluation of subsequent fracture risk:  Early secondary fracture risk evaluation is recommended due to high risk immediately after the fracture (3-6 months)
  6. Implementation of guidelines:  Implementation of guidelines should adapt to local needs and restrictions and should be based on collaboration between orthopedic surgeons, rheumatologists/endocrinologists, geriatricians (in case of elderly with a hip or other major fracture) and general practitioners
  7. Rehabilitation: Early post fracture introduction of physical training and muscle strengthening and the long-term continuation of balance training and multidimensional fall prevention should be incorporated in a rehabilitation protocol.
  8. Education: Patient education is recommended as an overarching principle and is incorporated in the guidelines as part of fracture prevention protocols. n a randomized study, a more personalized approach with a phone call plus follow-up letter to patients did not significantly increase osteoporosis follow-up care compared with simply sending out a letter.
  9. Non-pharmacological treatment: Although data on the effects of non-pharmacological treatment on fracture incidence are limited, vitamin D supplementation (800 IU/day), with adequate calcium intake, is associated with a 15%–20% reduction in non-vertebral fractures, and also with a 20% reduction in falls.
  10. Pharmacological treatment:  Pharmacological treatment should preferably use drugs that have been demonstrated to reduce the risk of vertebral, non-vertebral and hip fractures, and should be regularly monitored for tolerance and adherence.    Bisphosphonates (alendronate and risedronate) remain first-choice agents based on good tolerability, low cost and physician comfort level. Anabolic agents shall be reserved for severe cases.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

HERO Trial - Hydroxychloroquine Fails in Hand Osteoarthritis

UK researchers have treated 248 patients with moderate to severe hand pain and radiographic osteoarthritis (OA) and demonstrated no benefit after 12 months of hydroxychloroquine (HCQ), according to a recent article in Annals of Internal Medicine.

Teriparatide Superior to Risedronate in the VERO Trial

Lancet reports that in a study teriparatide with risedronate, post-menopausal women with severe osteoporosis had significantly fewer new vertebral and clinical fractures on teriparatide comared to those receiving risedronate.

This trial is one of the first to compare osteoporosis drugs with incident fractures as the primary outcome.

Two Types of Osteoarthritis Based on Cartilage Studies

A report from Annals of Rheumatic Diseases suggests that osteoarthritis (OA) may be two distinct diseases based on genetic studies of articular cartilage. (Citation source: https://buff.ly/2mNtUsL).

RNA sequencing of knee cartilage from 44 OA patients undergoing total knee replacement was compared to 6 additional patients with OA and 10 control patients with non-OA.

New Rise in Hip Fractures Amongst Women

Reuters reports that the incidence of hip fractures in older women in the U.S. is rising after more than a decade of decline, according to a large new study of Medicare recipients.

Calcium and Vitamin D Supplements Do Not Reduce Hip Fractures

Recent JAMA study shows metanalysis of 33 clinical trials and 51,145 participants, showed that calcium, vitamin D, or both affords no decreased risk of hip fractures compared with placebo or no treatment and therefore questions their routine widespread use in the elderly..